(Q40698016)

22 September 2017

1 reference

title

Antifungal drugs on the horizon (English)

1 reference

22 September 2017

Hay RJ

1

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 September 1994

1 reference

Journal of the American Academy of Dermatology

22 September 2017

published in

1 reference

22 September 2017

volume

31

1 reference

22 September 2017

issue

3 Pt 2

1 reference

22 September 2017

page(s)

S82-6

1 reference

Mode of action of morpholine derivatives

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Sensitivity to amphotericin B and the cholesterol: phospholipid molar ratios of 3T3, L, BHK and HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Amphotericin B-resistant yeast infection in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Distribution and activity of amphotericin B in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Overview of medically important antifungal azole derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Drug resistance in Candida albicans and Candida glabrata.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Saperconazole in the treatment of systemic and subcutaneous mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Antifungal activity of the allylamine derivative terbinafine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

In-vitro studies with SF 86-327, a new orally active allylamine derivative.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Preclinical data and mode of action of amorolfine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2981275-3

7 January 2021

10.1016/S0190-9622(08)81275-3

Identifiers

DOI

0 references

1 reference